Scoped author-reported evaluation; read protocol and cohort limits before comparing.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-09-30-e37e3ab1284d · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
1 evaluation · 54 results. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.3 overall_accuracy fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Fig1c Overall Accuracy; Section 3 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.75 diagnostic_micro_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, diagnostic row, alone column |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 diagnostic_negative_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Negative, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 diagnostic_negative_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Negative, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 diagnostic_negative_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Negative, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.86 diagnostic_positive_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Positive, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 1 diagnostic_positive_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Positive, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.75 diagnostic_positive_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Diagnostic / Positive, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.67 functional_dominant_negative_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Dominant Negative, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 1 functional_dominant_negative_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Dominant Negative, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.5 functional_dominant_negative_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Dominant Negative, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.57 functional_micro_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, functional row, alone column |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.67 functional_gain_of_function_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Gain of Function, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.75 functional_gain_of_function_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Gain of Function, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.6 functional_gain_of_function_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Gain of Function, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.55 functional_loss_of_function_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Loss of Function, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.6 functional_loss_of_function_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Loss of Function, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.5 functional_loss_of_function_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Loss of Function, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 functional_unaltered_function_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Unaltered Function, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 functional_unaltered_function_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Unaltered Function, precision |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0 functional_unaltered_function_recall fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Functional / Unaltered Function, recall |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.46 micro_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Fig1c Micro F1; Section 3 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.2 oncogenic_micro_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, oncogenic row, alone column |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.2 oncogenic_oncogenicity_f1 F1 score · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Oncogenic / Oncogenicity, f1 |
| Configuration: GPT-5 2025-08-07 alone, CIViC March 2026 | Protocol: CIViC evidence-direction retrieval, March 2026 Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026 | 0.25 oncogenic_oncogenicity_precision fraction · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 2, Oncogenic / Oncogenicity, precision |
Source checking is not independent reproduction. Release 2026-09-30-e37e3ab1284d.
Not reported
Metadata review: source checked. Unreported conditions prevent automatic comparisons.
No execution recipe has been verified for this exact configuration and evaluation. A benchmark's general instructions may use different inputs, splits or model settings.
Reproducing this published result requires matching its model configuration, data, split and scorer. Source checking or a successful smoke test does not establish score reproduction.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
18 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.comparison.adaptation Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.aggregation Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.budget Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.dataset_version Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.inputs Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.metric_implementation Source-defined endpoint; see result source_locator Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.population CIViC 100 molecular-profile/disease/therapy triplets, March 2026 Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.protocol_id uc-clinical-20260930-civic-retrieval-protocol Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.split Not reported Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.label_reference CIViC records; not independently adjudicated clinical truth Context-only references | CIViC MCP supplementary methods and complete Tables 1–3 Supplementary Tables 1–3; Fig1c Version: vbag209_supplementary_data.docx, final article supplement | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
View linked audit checks and correction history
Release 2026-09-30-e37e3ab1284d · Record review: source checked
Stable ID: uc-clinical-20260930-civic-alone-evaluation